Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jiawei Chuanxiong Chatiao San is a modified Traditional Chinese Medicine (TCM) herbal formulation based on the classical Chuanxiong Chatiao San prescription. It is primarily used in clinical practice for the treatment of various headache disorders, most notably migraine and tension-type headaches. The formulation typically consists of a complex mixture of botanical ingredients, including *Ligusticum chuanxiong*, *Angelica dahurica*, and *Mentha haplocalyx*, with the "Jiawei" designation indicating the addition of supplementary herbs to tailor the treatment to specific clinical patterns such as blood stasis or liver yang hyperactivity. Pharmacologically, the formula is thought to exert analgesic and vasorelaxant effects by modulating neurotransmitters like serotonin (5-HT) and neuropeptides such as calcitonin gene-related peptide (CGRP), as well as improving cerebral blood flow. It is frequently administered as an oral decoction or granule and is often evaluated in clinical trials as an adjuvant to Western therapies like flunarizine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on jiawei chuanxiong chatiao san.